血管生成与抗血管生成因子在子痫前期鉴别诊断中的价值
本文综述了子痫前期定义的演变及其对临床诊断的影响,指出新定义下更多孕妇被归为子痫前期但病情趋于轻度。血管生成与抗血管生成因子基于疾病病理生理,已成为高精度预测和诊断子痫前期的重要工具,sFlt-1/PlGF比值38可在1周内排除子痫前期(阴性预测值99.3%),比值85诊断子痫前期的灵敏度达88%、特异度99.5%。
要点
- 新定义下更多孕妇被归类为子痫前期,但疾病倾向更轻。
- sFlt-1/PlGF比值38阴性预测值99.3%,可1周内排除子痫前期。
- sFlt-1/PlGF比值85诊断子痫前期灵敏度88%、特异度99.5%。
核心结论
- 血管生成与抗血管生成因子是预测和诊断子痫前期的高精度可靠工具。
- 两个临床 cutoff 值(38 和 85)分别用于排除和诊断子痫前期。
研究设计与样本
- 综述类文章,检索范围未在摘要中报告。
主要发现
- sFlt-1/PlGF比值38排除子痫前期1周的阴性预测值为99.3%(95%CI 97.9-99.9),阳性预测值为36.7%(95%CI 28.4-45.7)。
- sFlt-1/PlGF比值85诊断子痫前期的灵敏度高达88%,特异度达99.5%。
- 新定义下更多孕妇被归类为子痫前期,但疾病倾向更轻。
关键数值与推荐
- sFlt-1/PlGF比值 cutoff 38:阴性预测值99.3%(95%CI 97.9-99.9),阳性预测值36.7%(95%CI 28.4-45.7)。
- sFlt-1/PlGF比值 cutoff 85:灵敏度88%,特异度99.5%。
临床怎么用
- 对疑似子痫前期孕妇可检测sFlt-1/PlGF比值辅助鉴别诊断。
- 比值38可用于短期(1周)排除子痫前期,比值85有助于确诊。
- 对慢性高血压或慢性肾脏病等高危孕妇,可结合生物标志物预测不良结局。
局限性
- 本文为综述,未报告原始研究的具体检索策略或纳入研究特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The definition of preeclampsia is changing. However, with the addition of organ symptoms to the presence of hypertension in pregnancy instead of relying only on proteinuria, a more precise detection of women at risk of preeclampsia-associated adverse events has not been achieved. Instead, under the new definitions of the American College of Obstetricians and Gynecologists and of the International Society for the Study of Hypertension in Pregnancy, more women are classified as preeclamptic, with a tendency to milder disease. Furthermore, angiogenic and antiangiogenic factors have emerged as essential tools for predicting and diagnosing preeclampsia at high accuracies. Next to being rooted in the pathophysiology of the disease, they have been proven to be reliable tools for predicting and diagnosing the disease. In addition, 2 cutoffs have been evaluated for the clinical setting. As shown in the Prediction of Short-Term Outcome in Pregnant Women With Suspected Preeclampsia Study, at the soluble fms-like tyrosine kinase-1-to-placental growth factor ratio cutoff of 38, a preeclampsia can be ruled out for 1 week with a negative predictive value of 99.3% (95% confidence interval, 97.9-99.9) and ruled in with a positive predictive value of 36.7% (95% confidence interval, 28.4-45.7). The diagnostic cutoff of 85 has been shown to accurately identify women with preeclampsia, with a sensitivity of up to 88% and a specificity of 99.5%. In this review, we highlight the central role of angiogenic and antiangiogenic factors in the differential diagnosis of women presenting at high risk of the disease, such as patients with chronic hypertension or chronic kidney disease. We will focus on their ability to predict preeclampsia-associated adverse fetal and maternal outcomes. This is only possible when critically reviewing the evolution of the definition of "preeclampsia." We show how changes in this definition shape our clinical picture of the condition and how angiogenic and antiangiogenic biomarkers might be included to better identify women destined to develop preeclampsia-related adverse outcomes.
引用
- Verlohren S, Dröge LA. The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. Am J Obstet Gynecol. 2020. PMID: 33002498. doi:10.1016/j.ajog.2020.09.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。